<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2011-10-31 10:43:00Autoimmune diseases Rare diseases National Institute of Arthritis and Musculoskeletal and Skin Diseases Arthritis Rheumatology NIH Intramural Research Program Glycogen storage disease type II Arthritis Foundation Rheumatoid arthritis Health Medicine National Institutes of Health |
Add to Reading List |
NIAMS IRPartners Spring/Summer[removed]A newsletter for | How one patient with a rare disease coped with his genetic disorderDocID: 1r9mW - View Document |
| LUMIZYME (alglucosidase alfa) for InjectionDocID: 1qeuI - View Document |
| United States Court of Appeals for the Federal Circuit ______________________ GENZYME THERAPEUTIC PRODUCTS LIMITED PARTNERSHIP,DocID: 1oYEH - View Document |
| Pompe disease (Glycogen storage disease type II) Glycogen storage disease type II is also known as acid maltase deficiency or generalized glDocID: 1lJGD - View Document |
| May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to ImDocID: 1aiEg - View Document |